base-metals-investing Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
base-metals-investing Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
base-metals-investing Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
base-metals-investing BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
base-metals-investing BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
base-metals-investing Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
base-metals-investing Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
base-metals-investing Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - October 02, 2025
base-metals-investing Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial
base-metals-investing Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
base-metals-investing Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - September 03, 2025
base-metals-investing Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
base-metals-investing Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Tartisan Nickel Corp. Appoints Jack Jacobs, Congressional Medal of Honour Recipient, Retired Army Colonel and Distinguished Business Executive to Board of Advisors
